Copyright © 2019. Inderes Oy. All rights reserved.
Search
User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
Herantis Pharma
1683 investors follow this company
The company is not covered. See all listed companies from here.
BUY 7.05 LOWEST 7.05 VOLUME 6 470
SELL 7.10 HIGHEST 7.20 VALUE 0,046 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Upcoming events

27
Feb
Tilinpäätöstiedotteet

Latest insider trading

Type: stock_exchange_release
30.12.
2019

Herantis Pharma Plc ("Herantis" or "Company") announced today an update on the development of its non-invasive next generation CDNF, or xCDNF. The xCDNF development program was initiated in July 2018 to develop cell-protecting molecules that penetrate the blood-brain barrier, building on the Company's cumulated expertise on CDNF, Herantis' lead compound in Parkinson disease.

Type: stock_exchange_release
20.12.
2019
Herantis Pharma Plc ("Herantis") will publish its Financial Statements in regard to 2019 on the 27[th] of February 2020. The financial reporting schedule of Herantis in 2020 is as follows:
  • Financial Statements bulletin in regard to 2019 on Thursday the 27[th] of February 2020
  • Interim Report on January-June 2020 on Thursday the 27[th] of August 2020

The Annual General Meeting is planned to be held on Wednesday the 8[th] of April 2020. The Board of Directors will present a formal notice at a later stage.

Type: stock_exchange_release
19.12.
2019

Herantis Pharma Plc ("Herantis" or "Company") announced today having completed patient treatments as planned in the main study of the Company's Phase 1-2 clinical trial examining Herantis' proprietary neuroprotective factor and novel drug candidate CDNF in patients with Parkinson's disease. Of the 17 patients randomized in the clinical trial, 15 patients completed the main study according to the study protocol and two patients discontinued due to reasons not related to CDNF.

Type: stock_exchange_release
17.12.
2019

Herantis Pharma Plc
Company release 17 Dec 2019 at 9:00 am

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Inveni Life Sciences Fund I Ky

Position: Closely associated person

(X) Legal person

(1):Person Discharging Managerial Responsibilities In Issuer

Name: Prihti, Aki

Position: Member of the Board

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Type: stock_exchange_release
16.12.
2019

Herantis Pharma Plc.
Company release, insider information 16 December 2019 at 5:00 PM

Type: stock_exchange_release
10.12.
2019

Herantis Pharma Plc has submitted a listing application to Nasdaq Stockholm AB for the listing of the offer shares

Herantis Pharma Plc
Company release 10 December 2019 at 4:00 PM EET

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Type: stock_exchange_release
9.12.
2019

Offer shares of Herantis Pharma Plc registered with the Trade Register

Herantis Pharma Plc
Company release 9 December 2019 at 3:00 pm EET

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Type: stock_exchange_release
2.12.
2019

Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned

Herantis Pharma Plc
Company release 2 December 2019 at 8:00 pm

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Type: stock_exchange_release
11.11.
2019

Herantis Pharma Plc commences a directed share issue, contemplates secondary listing on Nasdaq First North Growth Market Sweden and expands its management team

Herantis Pharma Plc
Inside information 11 November 2019 at 09:00 EET

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Type: stock_exchange_release
4.11.
2019

Herantis Pharma publishes newsletter for September-October

Herantis Pharma Plc
Press release 4 November 2019 at 9:00 am

Herantis Pharma plc (“Herantis”) has published its newsletter for September-October 2019. The newsletter is also attached to this press release.

Herantis Pharma

English translation unavailable for Herantis Pharma.
Herantis Pharma